Cipla Ltd announces board changes, investment in Cipla (EU) Ltd, and merger approval
Cipla · Pharmaceuticals & Biotechnology
Key highlights
- Mr P R Ramesh designated as Vice-Chairman effective 1 April 2026; Mr Robert Stewart to not seek re-appointment after 13 May 2026
- Approved investment of up to USD 100 million in Cipla (EU) Limited for financial assistance to InvaGen Pharmaceuticals Inc.
- Approved Scheme of Amalgamation of wholly owned subsidiary Inzpera Healthsciences Limited with Cipla Ltd, with no material financial impact
Why it's rated notable: amount is ₹500 crore or more
Original filing
Corporate Action-Amalgamation/ Merger / Demerger
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Cipla
- OtherNotableCipla Limited's Scheme of Amalgamation with Inzpera Healthsciences approved by NCLT
- Dividend / buyback / bonusMajor development· Adverse for the businessCipla announces Q4FY26 and FY26 audited results, dividend, and earnings call details
- Acquisition / mergerNotableCipla Ltd approves leadership changes, USD 100M investment, and subsidiary merger
Other acquisition / merger filings this fortnight
- IndiGrid Infrastructure Trust Q2 FY27 Earnings Conference Call Transcript Released
- Cubical Financial Services Ltd announces promoter reclassification post open offer
- Novus Loyalty Limited approves acquisition of AutoPe Payment Solutions via share swap
- Shish Industries Limited files Composite Scheme of Amalgamation proposal
- Jubilant Ingrevia Limited updates on acquisition of 40% stake in Zettaone Technologies
- NHC Foods approves quarter results, 99.98% Sachmaas Foods investment, two appointments
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.